IHC

Rockland Launches Novel Analytical Tools to Assess Drug Delivery: Revolutionizing Oligonucleotide Therapeutic Development

Retrieved on: 
Tuesday, October 17, 2023

LIMERICK, Pa., Oct. 17, 2023 /PRNewswire/ -- Rockland is a leading USA-based life science company, developing analytical tools that assist in the collection of pharmacodynamic, pharmacokinetic, and toxicology data critical for satisfying regulatory requirements for biological drugs, cell and gene therapies, and RNA therapeutic drugs (e.g., ASO, siRNA, mRNA). To date, Rockland has successfully generated reagents against many diverse nucleic acid chemical structures and modifications, including conventional oligonucleotides, DNA-RNA hybrids, single- and double-stranded RNA, and more.

Key Points: 
  • To date, Rockland has successfully generated reagents against many diverse nucleic acid chemical structures and modifications, including conventional oligonucleotides, DNA-RNA hybrids, single- and double-stranded RNA, and more.
  • Traditionally, ISH-type assays have been the mainstay method of detecting and localizing oligonucleotides in cells and tissues for nucleic acid therapy development.
  • Introducing the ModDetect™ Phosphorothioate (PS) Panel, an immunoassay-based alternative that provides robust detection of oligonucleotide therapeutic drug delivery and analysis, facilitating the collection of ADMET analytical data for regulatory approval.
  • ModDetect ™ is a growing suite of analytical tools generated against different types of nucleic acid chemical modifications.

Biocare Medical's IntelliPATH FLX™ Automated Slide Stainer: An Integral Part of EmeritusDX's Improved Diagnostic Workflow

Retrieved on: 
Wednesday, October 11, 2023

The integration of Biocare Medical's IntelliPATH FLX™ Automated Slide Stainer combined with Biocare's extensive menu of IHC antibodies, detection kits and ancillary reagents, into EmeritusDX's workflow marks a significant improvement in the efficiency and flexibility of their IHC testing.

Key Points: 
  • The integration of Biocare Medical's IntelliPATH FLX™ Automated Slide Stainer combined with Biocare's extensive menu of IHC antibodies, detection kits and ancillary reagents, into EmeritusDX's workflow marks a significant improvement in the efficiency and flexibility of their IHC testing.
  • Biocare Medical's IntelliPATH FLX™ is an automated slide stainer designed to optimize staining processes by offering a broad menu, precision, control, consistency and reliability.
  • The IntelliPATH FLX™ Automated Slide Stainer has proven essential in the accurate and reliable performance of their extensive IHC menu, including the Bladder17™ IHC test.
  • This partnership between Biocare Medical and EmeritusDX emphasizes a shared commitment to improving diagnostic processes through the effective utilization of innovative technologies and advanced workflow optimization.

Abu Dhabi's IHC Bets Big on Adani Enterprises, Says It Is Poised to Capitalize on India’s Growth Journey

Retrieved on: 
Wednesday, October 4, 2023

Abu Dhabi-based IHC has increased its stake in the Adani Group’s flagship incubator Adani Enterprises Ltd (AEL) to above 5%, it said on October 3, 2023.

Key Points: 
  • Abu Dhabi-based IHC has increased its stake in the Adani Group’s flagship incubator Adani Enterprises Ltd (AEL) to above 5%, it said on October 3, 2023.
  • This is more than what the company is expected to fetch from the stake sale in Adani Green Energy and Adani Energy Solutions.
  • IHC said the stake sale was part of a portfolio rebalancing strategy, adding that its partnership with Adani would continue.
  • This inter-generational relationship with IHC reflects well on India’s dynamic growth potential and offers substantial returns to our stakeholders.”

Lunit to Reveal 6 Abstracts at the SITC 2023 Annual Meeting

Retrieved on: 
Wednesday, September 27, 2023

SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of 6 abstracts featuring its Lunit SCOPE suite at the upcoming SITC 2023 (Society for Immunotherapy of Cancer 2023) Annual Meeting, scheduled to take place from November 1 to November 5, in San Diego, California.

Key Points: 
  • SEOUL, South Korea, Sept. 27, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced the presentation of 6 abstracts featuring its Lunit SCOPE suite at the upcoming SITC 2023 (Society for Immunotherapy of Cancer 2023) Annual Meeting, scheduled to take place from November 1 to November 5, in San Diego, California.
  • The highlighted abstracts for SITC 2023 include:
    By analyzing the tumor microenvironment (TME) with Lunit SCOPE IO, one study explores the treatment response of non-small cell lung cancer (NSCLC) patients with EGFR mutations to immune checkpoint inhibitors (ICI) after acquiring resistance to EGFR tyrosine kinase inhibitors (TKI).
  • Visit Lunit's booth at SITC 2023 at Booth 227 to learn more about these pioneering studies.
  • To schedule a meeting with the Lunit team, please reach out to [email protected] .

Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Retrieved on: 
Friday, September 22, 2023

The safety profile of datopotamab deruxtecan was consistent with previous clinical trials in breast cancer with no new safety signals identified.

Key Points: 
  • The safety profile of datopotamab deruxtecan was consistent with previous clinical trials in breast cancer with no new safety signals identified.
  • Daiichi Sankyo and AstraZeneca have two additional phase 3 trials evaluating datopotamab deruxtecan in breast cancer.
  • TROPION-Breast02 is comparing datopotamab deruxtecan to chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic triple negative breast cancer (TNBC) who are not candidates for anti-PDL1 therapy.
  • TROPION-Breast03 is evaluating datopotamab deruxtecan with and without durvalumab versus investigator’s choice of therapy in patients with stage I-III TNBC with residual disease after neoadjuvant therapy.

Sensorion Reports 2023 First Half Results

Retrieved on: 
Wednesday, September 20, 2023

In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV OTOF-GT batches at 200L clinical scale.

Key Points: 
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV OTOF-GT batches at 200L clinical scale.
  • In April 2023, Sensorion announced the candidate selection for GJB2-GT during its R&D Day focusing on gene therapy.
  • The first patient was enrolled in December 2022 and Sensorion anticipates the publication of the preliminary results in H2 2023.
  • The annual accounts on June 30, 2023, drawn up according to IFRS standards and approved by the Board of Directors on September 18, 2023.

NanoString Launches the Most Comprehensive Spatial Proteomics Panel Ever Offered

Retrieved on: 
Wednesday, September 13, 2023

The GeoMx IO Proteome Atlas (IPA) is the industry’s most comprehensive spatial proteomics assay, enabling spatial profiling of more than 500 immuno-oncology (IO) relevant targets from FFPE (Formalin-Fixed, Paraffin-Embedded) tissue sections.

Key Points: 
  • The GeoMx IO Proteome Atlas (IPA) is the industry’s most comprehensive spatial proteomics assay, enabling spatial profiling of more than 500 immuno-oncology (IO) relevant targets from FFPE (Formalin-Fixed, Paraffin-Embedded) tissue sections.
  • Containing IHC-compatible antibodies entirely from abcam ’s extensive IO portfolio, the GeoMx IPA provides an extraordinary advancement in the field of spatial proteomics.
  • “The GeoMx IPA represents the convergence of two of the most dynamic fields in biomedical research: spatial biology and high-plex proteomics,” said Brad Gray, President and CEO of NanoString.
  • Most recently, NanoString and abcam announced the inclusion of abcam-validated antibodies in the first 64-plex panel for NanoString’s CosMx™ Spatial Molecular Imager.

Acutis Biosciences' CSO Dr. Abdel Halim Co-Authors a Precision Medicine Study in NEJM

Retrieved on: 
Thursday, September 7, 2023

Study demonstrates the clinical value of circulating tumor DNA (ctDNA) in molecular profiling.

Key Points: 
  • Study demonstrates the clinical value of circulating tumor DNA (ctDNA) in molecular profiling.
  • The study demonstrated the clinical value of circulating tumor DNA (ctDNA) in molecular profiling to assess patient's eligibility for targeted therapeutics.
  • With ctDNA blood samples you are guaranteed as low as 1% failure rate compared to tumor tissues" said Dr. Halim.
  • Acutis CEO Jibreel Sarij added, "Dr. Halim and his team are making significant impact to bring forward clinical research testing and genomic profiling to enable biopharma with deeper insights and transform precision medicine".

Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer

Retrieved on: 
Thursday, September 7, 2023

ANN ARBOR, Mich., Sept. 7, 2023 /PRNewswire/ -- Strata Oncology, Inc. ("Strata"), a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced new data showing its proprietary biomarker algorithm, Immunotherapy Response Score (IRS), supports informed clinical decisions for first-line treatment of patients with non-small cell lung cancer (NSCLC) beyond the standard of care biomarker PD-L1 immunohistochemistry (IHC).

Key Points: 
  • ANN ARBOR, Mich., Sept. 7, 2023 /PRNewswire/ -- Strata Oncology, Inc. ("Strata"), a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced new data showing its proprietary biomarker algorithm, Immunotherapy Response Score (IRS), supports informed clinical decisions for first-line treatment of patients with non-small cell lung cancer (NSCLC) beyond the standard of care biomarker PD-L1 immunohistochemistry (IHC).
  • Strata Oncology announces data supporting utility of IRS score to guide first-line treatment decisions in NSCLC.
  • IRS can potentially guide treatment selection in this important and frequent clinical scenario," said Kat Kwiatkowski, Ph.D., Strata Oncology SVP, Clinical Development.
  • Immunotherapy Response Score is available clinically as part of the Strata SelectTM test, which is covered for Medicare beneficiaries with advanced solid tumors seeking additional treatment.

Ibex Launches Galen™ Breast HER2, Supporting Improved Biomarker Scoring in Breast Cancer Patients

Retrieved on: 
Thursday, September 7, 2023

TEL AVIV, Israel, Sept. 7, 2023 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced the launch of Galen™ Breast HER2, an AI-powered solution that aids pathologists in setting a higher standard for accurate and reproducible HER2 (human epidermal growth factor receptor 2) scoring in breast cancer patients.

Key Points: 
  • HER2, one of the proteins responsible for division and proliferation of breast cancer cells, is expressed in many breast tumors and its accurate assessment is critical for identifying patients who are likely to benefit from HER2-directed therapies.
  • Traditionally, pathologists evaluate HER2 in tumor samples visually, which may result in varied interpretations as scoring is semi-quantitative and thus somewhat subjective1.
  • Galen Breast HER2 was developed and validated by Ibex in collaboration with AstraZeneca and Daiichi Sankyo .
  • Information about Galen Breast HER2 and Galen Breast will be available at the 35th European Congress of Pathology in Dublin, Ireland, between September 9-13 (Ibex Medical Analytics - booth number 23).